Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vandetanib - AstraZeneca

Next Previous
Drug Profile

Vandetanib - AstraZeneca

Alternative Names: AZD 6474; Caprelsa; SAR 390530; Zactima; ZD 6474; Zictifa

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Fox Chase Cancer Center; Hoosier Cancer Research Network; Sanofi; University of Oxford
  • Class Antineoplastics; Bromobenzenes; Fluorobenzenes; Piperidines; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; Proto oncogene protein c ret inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thyroid cancer
  • Phase II Malignant melanoma; Small cell lung cancer
  • No development reported Brain metastases; Gastrointestinal cancer
  • Discontinued Biliary cancer; Breast cancer; Colorectal cancer; Head and neck cancer; Liver cancer; Malignant pleural effusion; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 14 Feb 2023 Genzyme completes the phase III ZEAL trial in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Late stage disease, Metastatic disease) in USA, Argentina, Australia, Belgium, Colombia, France, Germany, Greece, Hong Kong, India, Israel, Italy, Mexico, Philippines, Portugal, South Africa, Spain, Sweden, Taiwan, Venezuela and United Kingdom (IV) (NCT00418886) (EudraCT2006-003695-35)
  • 10 May 2018 AstraZeneca suspends patient enrolment in the phase II ZACFAST trial due to drugs unavailable for Breast cancer in USA (PO) (NCT01934335)
  • 09 Dec 2017 AstraZeneca re-initiates the phase III VERIFY trial for Thyroid cancer (Late-stage disease) in USA, Brazil, China, Japan, Russia, Denmark, France, Italy, Poland, Spain, Czechia and Sweden (PO) (NCT01876784)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top